IntersectMSK Lecture Series
June 8th • RRL 117 • 2:00 P.M.
Dawning Era of Accountable Care Organizations:
Impact on Healthcare Delivery
Barbara Ossias is the Principal for Reimbursement Revenue Solutions, a healthcare consulting firm serving both end users and manufacturers in all areas of healthcare including medical imaging, radiation oncology and radiation therapy.
Barbara’s firm assists manufacturers in strategically positioning their respective organizations for success, providing support in a variety of aspects of healthcare management, planning and implementation reimbursement strategies for products for prime market positioning, pre-market research on predicate technologies. Prior to entering the U.S. market, they assist companies with PMAs, strategic reimbursement planning and implementation, clinical trial reimbursement, pricing strategies and implementation.
Clients include Accuray, Alliance Health, Bayer Healthcare Pharmaceuticals, Baxter, Bio Gen, Cardinal Health, Covidien, Genentech, InSightec, Mallinckrodt, Quest Medical, Philips Medical NE, Repligen, Siemens, Slate Pharma, Spinal Integrity, Sprout Pharma, Zevacor Pharma, Merck and Roche.
Dr. Craig Samitt is executive vice president and chief clinical officer for Anthem, Inc., and is responsible for establishing, leading and executing Anthem's overall clinical vision and strategy. Dr.
Samitt oversees Anthem’s clinical operations including: health care analytics, corporate medical and pharmacy policy, health care management and quality, program integrity, and community health initiatives. He is also responsible for advancing Anthem’s industry-leading portfolio of provider partnerships and payment innovation models, focused on improving patient outcomes and delivering value-based care to Anthem’s 38.6 million medical members. Additionally, Dr. Samitt has responsibility for HealthCore, Anthem’s clinical outcomes research subsidiary, and AIM Specialty Health, Anthem’s specialty benefits management
Prior to joining Anthem, Dr. Samitt served as partner and global provider practice leader of Oliver Wyman’s Health & Life Sciences division; president and chief executive officer for HealthCare Partners, a subsidiary of DaVita HealthCare; and president and CEO of Dean Health System, Inc.
Dr. Samitt is serving a second three-year term as a Commissioner for MedPAC, an independent legislative branch agency established and appointed by the U.S. Government Accountability Office to advise Congress on policies impacting Medicare beneficiaries. He is also on the Board of Directors of the National Committee for Quality Assurance (NCQA) and is a Member of the National Academy of Medicine (NAM) Leadership Consortium for Value & Science-Drive Health Care.
Dr. Samitt earned his medical degree from Columbia University and completed medical residency at Boston’s Brigham and Women’s Hospital. He also holds an MBA in health care management from the Wharton School of Business.
Dr. Jonca Bull serves as Assistant Commissioner for Minority Health, US Food and Drug Administration. She is a member of the Senior Staff, interfacing with all product centers. Dr. Bull brings extensive public and private sector experience in dealing with a range of medical product development and diversity issues to this important position.
Dr. Bull returned to FDA after serving as Vice President for US Drug Regulatory Policy at Novartis and, prior to that, as Director of Clinical Regulatory Policy at Genentech. Dr. Bull previously served in FDA in a variety of leadership positions in both the Center for Drug Evaluation and Research (CDER) and the Office
of the Commissioner. Dr. Bull also previously spent eleven years providing clinical care in a multi-specialty group practice.She holds an appointment as an Assistant Clinical Professor at George Washington University Medical Center. Dr. Bull is a graduate of Princeton University and received her medical degree from Duke University School of Medicine. She did her postgraduate training at George Washington University, is board certified in Ophthalmology, and is a fellow of the American Academy of Ophthalmology.
Dr. Lola A. Fashoyin-Aje is a medical officer in the Office of Oncology and Hematology Products (OHOP) in the Center for Drug Evaluation and Research at the Food and Drug Administration. Her work focuses on the evaluation of investigational new drug applications and marketing applications for oncologic drugs and biologics for the treatment of solid tumor malignancies. She is the chair of the Disparities Working Group at OHOP and leads the Office’s efforts to improve inclusion of diverse demographic subgroups in cancer clinical trials. Prior to joining the FDA, Dr. Fashoyin-Aje completed her residency in internal medicine and fellowship in medical oncology at Johns Hopkins. She is a graduate Columbia University, and received her MPH and medical degree at Yale University and University of Rochester,